Baylor Scott & White Research Institute

Running trials

• Not yet recruiting

  Scale-Up Evaluation Trial of the Diabetes Prevention Program to Improve Obesity and Cardiometabolic Health After Traumatic Brain Injury

  NCT07648901· Baylor Research Institute· Source

• Recruiting

  EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

  NCT07287670· Phase 2· Mediar Therapeutics· Source

• Recruiting

  A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

  NCT07325526· Phase 2· Boehringer Ingelheim· Source

• Enrolling by invitation

  Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma

  NCT07212491· Mayo Clinic· Source

• Recruiting

  BoxX-NoAF Clinical Trial

  NCT06989775· AtriCure, Inc.· Source

• Active, not recruiting

  A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

  NCT07015983· Phase 2· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Recruiting

  Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.

  NCT07048808· Phase 2· XyloCor Therapeutics, Inc.· Source

• Recruiting

  Alleviant ALLAY-HFrEF Study

  NCT06812533· Alleviant Medical, Inc.· Source

• Active, not recruiting

  A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

  NCT06588686· Phase 2· Vicore Pharma AB· Source

• Recruiting

  Efficacy of a Telehealth Delivered Group Lifestyle Balance for People Post Stroke (tGLB-CVA)

  NCT06569121· Baylor Research Institute· Source

• Recruiting

  Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

  NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Active, not recruiting

  P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

  NCT06014762· Phase 1· Poseida Therapeutics, Inc.· Source

• Recruiting

  Spinal Cord Injury Model Systems (SCIMS) - Education Module

  NCT06003686· University of Miami· Source

• Enrolling by invitation

  An Observational Study of Patients With Chronic Liver Disease

  NCT05744713· Target PharmaSolutions, Inc.· Source

• Active, not recruiting

  A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

  NCT06109272· Phase 2/3· AbbVie· Source

• Recruiting

  BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

  NCT06059638· Orchestra BioMed, Inc· Source

• Recruiting

  MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

  NCT06128629· Phase 3· Intellia Therapeutics· Source

• Recruiting

  Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  NCT06047379· Phase 1/2· Neonc Technologies, Inc.· Source

• Recruiting

  A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

  NCT05765812· Phase 1/2· Debiopharm International SA· Source

• Active, not recruiting

  Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease

  NCT05755711· Shockwave Medical, Inc.· Source

• Recruiting

  Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

  NCT04124120· Weill Medical College of Cornell University· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  NCT05503797· Phase 2· Fore Biotherapeutics· Source

• Active, not recruiting

  Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (ELEPHAS-01)

  NCT05478538· Elephas· Source

• Recruiting

  Alleviant ALLAY-HF Study

  NCT05685303· Alleviant Medical, Inc.· Source

• Recruiting

  Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics

  NCT05736029· OncoHost Ltd.· Source

• Active, not recruiting

  BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

  NCT05120271· Phase 1/2· Sotio Biotech Inc.· Source

• Active, not recruiting

  Clinical Trial on Agitation in Alzheimer's Dementia

  NCT05543681· Phase 2· IGC Pharma, LLC· Source

• Recruiting

  A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

  NCT05489705· Bristol-Myers Squibb· Source

• Active, not recruiting

  Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

  NCT05389215· Phase 2· Daewoong Pharmaceutical Co. LTD.· Source

• Active, not recruiting

  LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321420· Phase 2· PureTech· Source

• Active, not recruiting

  RADIANCE Continued Access Protocol

  NCT05017935· ReCor Medical, Inc.· Source

• Recruiting

  A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  NCT04879329· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

  NCT04911478· Adicet Therapeutics· Source

• Recruiting

  Assessment of CCM in HF With Higher Ejection Fraction

  NCT05064709· Impulse Dynamics· Source

• Active, not recruiting

  INSPIRE Pipeline™ Shield Post Approval Study

  NCT05071963· Medtronic Neurovascular Clinical Affairs· Source

• Enrolling by invitation

  Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs

  NCT04930289· Paragonix Technologies· Source

• Recruiting

  STRIVE Post-Market Registry Study

  NCT04302272· Olympus Corporation of the Americas· Source

• Recruiting

  A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

  NCT04786262· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

  NCT04657081· Phase 1/2· Taiho Oncology, Inc.· Source

• Active, not recruiting

  Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

  NCT04229979· Phase 3· Sellas Life Sciences Group· Source

• Active, not recruiting

  A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

  NCT04404660· Phase 1/2· Autolus Limited· Source

• Active, not recruiting

  Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma

  NCT03878550· Glycotest, Inc.· Source

• Active, not recruiting

  The CONFORMAL Early Feasibility Study

  NCT03616028· Conformal Medical, Inc· Source

• Recruiting

  Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

  NCT03536312· Ottawa Heart Institute Research Corporation· Source

• Recruiting

  Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

  NCT04088071· Heart Rhythm Clinical and Research Solutions, LLC· Source

• Recruiting

  Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes

  NCT01904851· Baylor Research Institute· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure4 recruiting
• Bladder cancer3 recruiting
• Atrial fibrillation2 recruiting
• COPD2 recruiting
• Coronary artery disease2 recruiting
• Glioblastoma2 recruiting
• High blood pressure2 recruiting
• Liver cirrhosis2 recruiting
• Lung cancer2 recruiting
• Obesity2 recruiting
• Amyloidosis1 recruiting
• Aortic aneurysm1 recruiting
• Barrett's oesophagus1 recruiting
• Brain metastases1 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Cystic fibrosis1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Myasthenia gravis1 recruiting
• Ovarian cancer1 recruiting
• Peripheral artery disease1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Spinal cord injury1 recruiting
• Stroke1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thyroid cancer1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)

  NCT05966662· Shockwave Medical, Inc.· Source

• Terminated

  A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

  NCT05515406· Phase 1· Ono Pharmaceutical Co., Ltd.· Source

• Completed

  Endovascular Engineering ENGULF Study

  NCT05597891· Endovascular Engineering· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Cassava Sciences, Inc.· Source

• Terminated

  Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

  NCT05318105· Nuwellis, Inc.· Source

• Terminated

  Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

  NCT05275439· Phase 1· Shattuck Labs, Inc.· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System

  NCT04129125· Imperative Care, Inc.· Source

• Completed

  Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma

  NCT03961945· Mayo Clinic· Source

• Completed

  Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

  NCT04472429· Phase 3· Incyte Corporation· Source

• Terminated

  Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

  NCT04502316· CVRx, Inc.· Source

• Terminated

  A Study of TAS1440 With ATRA in Subjects With r/r AML

  NCT04282668· Phase 1· Taiho Oncology, Inc.· Source

• Completed

  Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

  NCT04068181· Phase 2· Amgen· Source

• Recruiting

  Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

  NCT04739072· M.D. Anderson Cancer Center· Source

• Recruiting

  Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

  NCT02781883· Phase 2· Bio-Path Holdings, Inc.· Source

• Completed

  Zenith® p-Branch® Endovascular Graft Pivotal Study

  NCT02396199· Cook Research Incorporated· Source

• Recruiting

  Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis

  NCT03256240· Weill Medical College of Cornell University· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure161 works · 7 trials
• High blood pressure6 works · 3 trials
• Barrett's oesophagus3 works · 2 trials